455 Pennsylvania Avenue
10 articles with Biocoat, Inc.
Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings, services and dip-coating equipment for medical devices, today announced that its HYDAK® UV coating has been approved for a patent by the United States Patent and Trademark Office (USPTO).
Biocoat, Inc. Launches Coating Equipment Business Unit; Completes Full-Service Hydrophilic Coating Offering
Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings and coating equipment for medical devices, announced its expansion into the design, development and delivery of hydrophilic dip coating equipment.
Biocoat, Inc. Expands Business Development Team; Adds Joshua de Freitas as Business Development Director
De Freitas joins Biocoat to support expanding hydrophilic coating products and coating service offerings that aid in development programs for medical device companies.
Nelson to lead business development efforts to educate and inform medical device companies on new product offerings for growing hydrophilic coating provider.
Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings for medical devices, today announced the launch of HYDAK® UV.
Plank to lead customer relationship management for expanding hydrophilic coating provider
Biocoat, Inc., a specialty manufacturer of hydrophilic biomaterial coatings for medical devices, today announced that the company has launched an ISO-certified, full-service on-site facility for the application of its HYDAK® coatings to its customers unique medical devices
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Bell to lead financial growth planning for leading biomaterial coatings company
Biocoat, Inc., (Biocoat) a 27-year old privately held company, announced today that it has been acquired by 1315 Capital, a Philadelphia-based healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty pharmaceutical companies.